Jain PharmaBiotech, Feb 2012, Pages: 659
Future prospects of genetherapy of cardiovascular disorders
8. Genetherapy of viral infections
Introduction
Acquired Immunodeficiency Syndrome (AIDS)
Current management of AIDS
Genetherapy
Jain PharmaBiotech, Feb 2012, Pages: 1008
of cell therapy for heart disease
A critical evaluation of cell therapy for heart disease
Publications of clinical trials of cell therapy for CVD
Currentstatus of cell therapy for cardiovascular disease
Jain PharmaBiotech, Feb 2012, Pages: 345
Rationale
Techniques of genetherapy for PD
Prospects of genetherapy for PD
Companies developing genetherapy for PD
RNAi therapy of Parkinson's disease
Alzheimer disease
Drug delivery for Alzheimer
Jain PharmaBiotech, Feb 2012, Pages: 276
-arginine to NO. NOS can be stimulated as well as inhibited by pharmacological and genetherapy approaches.
Important therapeutic areas for NO-based therapies are inflammatory disorders, cardiovascular
Jain PharmaBiotech, Feb 2012, Pages: 628
chelators, ion channel modulators and genetherapy. Some of the agents are old established pharmaceuticals whereas others are new biotechnology products.
Pathomechanisms of diseases are described with steps
Jain PharmaBiotech, Feb 2012, Pages: 780
with ACT
Genetically targeted T cells for treating B cell malignancies
Genetic engineering of tumor cells
Hybrid cell vaccination
Personalized peptide cancer vaccines
Currentstatus and future prospects
Jain PharmaBiotech, Feb 2012, Pages: 772
penetration is improved in transdermal drug delivery. A particularly effective application is as nonviral genetherapy vectors. Nanotechnology has the potential to provide controlled release devices
Jain PharmaBiotech, Feb 2012, Pages: 481
for treatment of viral infections
Promise and pitfalls of RNAi genetherapy
Management of rapidly evolving pathogens
Personalized medicine and viral diseases
An integrated approach to viral diseases
Current
Jain PharmaBiotech, Feb 2012, Pages: 864
imaging
Positron emission tomography
Advantages of imaging biomarkers
Monitoring in vivo gene expression by molecular imaging
Molecular imaging in vivo as a biomarker
Challenges and future prospects
Global Industry Analysts, Inc., Oct 2011, Pages: 897
GeneTherapy 33
6. IMMUNOTHERAPY 34
Current and Future Analysis 34
Table 9: Global Market for Immunotherapy (2007 and 2012):
Percentage Breakdown of Revenues by Drug Class - Monoclonal
Antibodies
John Wiley and Sons Ltd, April 2008, Pages: 432
. Radioprotective genetherapy: currentstatus and future goals (Joel S. Greenberger and Michael W. Epperly).
21.1 Introduction.
21.2 Organ-specific radiation protection: oral cavity/oropharynx.
21.3 A potential
TriMark Publications, July 2007, Pages: 270
Healing: Skin and Soft Tissue Repair 139 6.7.1 Autologous Living Cell Therapy 139 6.7.2 Cell Therapy for Corneal Repair 140 6.7.2.1 Current Clinical Status for Cornea Disease and Transplant 140 6
Biophoenix Limited, Feb 2009, Pages: 312
of new anticancer drugs. Wider application of validated biomarkers of apoptosis in preclinical and clinical trials of new drugs is thus highly desirable. - The utility of current anticancer therapies
Axis Research Mind, Nov 2011, Pages: 342
by the PCR industry, even during the recession years, confirms the positive growth prospects going ahead. Among the major developments in the recent years, gene amplification technology indicates the highest
Datamonitor, Dec 2010, Pages: 365
are the commercial prospects of current and potential therapies for Parkinson's disease over the next 10 years?
- How will the impact of recent patent expiries and new product launches affect the Parkinson’s disease
Decision Resources, Inc., July 2005, Pages: 107
therapies. We group other orphan drugs in this report according to their primary mode of action: enzymes and enzyme inhibitors, hormones, genetherapies, gene modulators, monoclonal antibodies, and receptor
Spectra Intelligence, April 2006, Pages: 369
to 2016
- The currentstatus of cancer chemotherapy in general and with regard to specific types of cancer
- The major issues involved in the research and development of chemotherapies
- Which types
Business Insights, Dec 2010, Pages: 215
of action of botanical drugs.
While China in particular can boast the successful innovation of novel drugs (genetherapies) ahead of companies in the West, it is notable that regulatory approvals
Axis Research Mind, Nov 2011, Pages: 644
by the PCR industry, even during the recession years, confirms the positive growth prospects going ahead.
Among the major developments in the recent years, gene amplification technology indicates the highest
Business Insights, Sep 2008, Pages: 253
"The total RNAi therapy market is estimated to value $580m by 2012. This forecast is based upon current treatments, levels of market satisfaction and five new Phase II/III RNAi agents profiled
